Immunoaffinity LC-MS/MS or hybrid LC-MS/MS is an approach that has been gaining a lot of traction in the past several years.  The technique allows the quantitation of low-level analytes (proteins or peptides in many cases) in biological matrices with exquisite selectivity and sensitivity. Many pharmaceutical companies are trying to expand…

Anyone who has been following KCAS for any amount of time has likely heard us discuss the advantages of Hybrid LC-MS/MS for the bioanalysis of large molecules. As pioneers in the technology for many years, KCAS has become a strong proponent of working with our customers to demonstrate the quality…

For years, Dawn Dufield, PhD and I have been doing our best to get the word out (via as many venues as possible) about KCAS’s unique expertise with hybrid LC-MS/MS. This year’s upcoming EBF meeting in Barcelona is just such an opportunity, and one we are very much looking…

Due to the relative maturity of the technology, most people’s instinct when thinking about bioanalysis of large molecules is towards ligand binding assays. However, we urge people to be open to a more flexible approach. Using hybrid LC-MS/MS can be an equally useful tool for quantitation of biological therapeutics and…

For researchers and professionals working in the biopharmaceutical industry, an upcoming Bioanalysis Zone Panel Discussion will offer a unique opportunity to stay informed about the latest advancements in quantitative analysis techniques. Research projects can only succeed when selecting the appropriate biopharmaceutical quantification technique. Staying up-to-date on…

Originally produced by Xtalks on Friday, April 22, 2022 | 12pm EDT (NA) / 5pm BST (UK) / 6pm CEST (EU-Central)  60 min Webinar Description: Due to the relative maturity of the technology, most people’s instinct when thinking about bioanalysis of large molecules is towards ligand binding assays.

There has been an increasing focus on large molecule therapeutics and pharmaceutical companies have increasingly aligned their development pipelines in that direction. This has resulted in more biological therapeutics coming to market.  Last year,…

In the complex and dynamic bioanalytical landscape of antibody-drug conjugate (ADC) services, where often time is critical and every research dollar counts, hybrid technology is quickly emerging as a game-changer. Hybrid offers a spectrum of advantages that redefine traditional approaches to bioanalytical ADC drug development. At the forefront of these…

Dawn Dufield, Ph.D. and Dominic Warrino, Ph.D. discuss their approach to ligand binding assays (LBAs) and hybrid mass spectrometry (Hybrid LC-MS/MS) in this 11-part video series. What Makes a Good CRO for Bioanalysis? Are there any specific technologies that are more useful to have together? What is a Hybrid…

What is Hybrid LC-MS/MS? Technically Hybrid LC-MS/MS is a technique that combines an affinity capture step with LC-MS/MS detection. Usually it only requires one antibody, whereas a typical LBA technique will require two. Following affinity capture, it is common to include a digestion step to produce surrogate peptides, which are…

If you are part of the Biotech/Pharma community, you may be familiar with the (J.P. Morgan) JPM Healthcare Conference that takes place annually in January and typically in San Francisco. This was the 42nd Annual JPM Healthcare Conference and it is the world’s largest healthcare symposium. This year the mood…

Is Hybrid LC-MS/MS emerging as an Equal Partner? Click here to view the entire series.

What is a Hybrid LC-MS/MS? Click here to view the entire series.

Special guests Dawn Duffield, PhD of KCAS and Barry Jones, PhD of Crinetics join John and Dom in the 66th episode of “The Weekly Bioanalysis” to discuss the ways Hybrid LC-MS/MS has advanced in recent years and how the technology has gone from “new” and somewhat obscure to…

Knowledge for Growth (KfG) is Europe’s premier life sciences conference, held annually in Antwerp, Belgium. This year’s edition celebrates the industry’s advancements with a hybrid format, catering to both in-person and virtual attendees. The program features captivating talks, scientific sessions on cutting-edge topics like gene editing and personalized medicine, and…

Along with a series of studies we plan to present related to our experiences with hybrid LC-MS/MS technology, KCAS will also be presenting on a study where we analyzed a compound that involved looking at urea in plasma and lung fluid (urea, of course, being a biomarker). Urea is endogenous…

Ligand binding assays (LBAs) have been our core activity for decades. LBAs are commonly used to measure interactions between two proteins, a ligand and its receptor, a monoclonal antibody (mAb) and its target, or biologics and Anti-Drug Antibodies (ADA). Throughout the…

To read part one of this 2-part series, click here. With increasing focus on large molecule therapeutics and interest in large molecule biomarkers it’s essential to have LC/MS available as a complimentary technology to ligand…

Biomarker is a broad term and can mean so many different things depending upon the scientific discipline. For Bioanalytical biomarker analysis – and specifically for CROs equipped with 9 different platforms to measure biomarkers and a cell culture suite with up to 19 color flow cytometry all under one roof…

The 505(b)(2) drug development path, in contrast to traditional development of a new, never been approved drug (described under 505(b)(1) of the Federal Food, Drug, and Cosmetic Act) or ANDA (described under Section 505(j) of the Act) for a generic drug that is no longer under patent…

Dawn Dufield, PhD is the Scientific Officer for Mass Spectrometry and has been with KCAS Bio since 2018. Before joining KCAS Bio, she worked in the quantitative large and small molecule LC-MS/MS field for Pfizer for over 20 years. Dawn has been a pioneer in the Hybrid LCMS field and…

Dom & Dawn’s Opinion on the CRO Industry? Click here to view the entire series.

Do You Feel that Many Bioanalytical CROs are Quick to Cover All of These Technologies? Click here to view the entire series.

What are Some Scenarios Where More Than One Approach is Needed? Click here to view the entire series.

Do You Have Examples of When You Started with One Testing Platform and Switched to Another? Click here to view the entire series.

How do You Know Which Approach is Best? Click here to view the entire series.

Are the Sensitivities Similar? Click here to view the entire series.

What are the Differences Between Time and Costs for Development? Click here to view the entire series.

Are there any specific technologies that are more useful to have together? Click here to view the entire series.

What Makes a Good CRO for Bioanalysis? Click here to view the entire series.

Biomarker are key drivers in the drug development process.  Frequently, developing a panel of biomarkers to test a particular mechanism or hypothesis is critical to the success of a drug.  At KCAS, we develop assays for custom panels or individual biomarkers based on client needs and can also assist with…

Produced by AAPS Organized by Sciex Recorded on December 6, 2023 eChalkTalk available here.  Webinar Description: In this webinar, scientists from KCAS Bio, along with specialists from SCIEX Biopharma & Pharma Solutions discuss • Developing robust assays for PD biomarkers and their challenges…

With recent guidance released from the FDA, there are changes for PKs (Pharmacokinetics) and ADCs (Antibody Drug Conjugates) that must be clearly understood before making decisions for your drug product testing. ADCs combine the target specificity of monoclonal antibodies with the…

With the extensive advances in technologies like CRISPR and CAR-T, cell and gene therapy has grown to become a viable way for treating Cancer as well as other diseases. Our team has over 100+ years of collective expertise in molecular services using qPCR and ddPCR for support of…

Cell and Gene Therapies (CGTs) are types of treatment that uses cellular or genetic material with the goal of treating a disease or a disordered. Often it can be a combination of cell and gene therapies, which is the case for Chimeric antigen receptor T cells (CAR T-Cells).  As of…

Pharmacodynamics (PD) is defined as the study of the biochemical and physiological effects of drugs and the mechanisms of their actions. Where pharmacokinetics looks at how the organism processes the drug, pharmacodynamics studies how…

KCAS is a solution-based company. We are focused on the delivery of high quality scientific and defendable data, able to meet or exceed client’s timelines and expectations. One of the main reasons we are able to deliver on even the most challenging projects and programs, is the technical breadth and…